Biodistribution of [89Zr]DFO-Maleimide-VLP-1 in Wistar Rats by Positron Emission Tomography (PET)

被引：0
|
作者：
Riffel, Kerry [1 ]
Haley, Hyking [2 ]
Wang, Yuchuan [1 ]
Purcell, Mona [2 ]
Zhang, Yingyue [1 ]
Chiang, Yunshan [1 ]
Abend, Andreas [1 ]
Li, Wenping [2 ]
机构：
[1] Merck & Co Inc, Rahway, NJ USA
[2] Merck Res Labs, Rahway, NJ USA
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2023年 / 126卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-201
引用
收藏
页码：S208 / S209
页数：2
相关论文
共 43 条
  • [21] Radiation Dosimetry Study of [89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography
    Natarajan, Arutselvan
    Gambhir, Sanjiv Sam
    MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (04) : 539 - 547
  • [22] Dose Rates and Patient Contact Restrictions Following Zirconium-89 (Zr89) Positron Emission Tomography (PET) Studies
    Wright, G.
    Papadopoulos, E.
    Saleem, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S223 - S223
  • [23] Radiation Dosimetry Study of [89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography
    Arutselvan Natarajan
    Sanjiv Sam Gambhir
    Molecular Imaging and Biology, 2015, 17 : 539 - 547
  • [24] The value of Zirconium-89 Positron Emission Tomography (89Zr-PET) during the phase 1 study of a new antibody construct: 89Zr-labeled cergutuzumab amunaleukin as an example
    de Wit-van der Veen, B. J.
    Huisman, M.
    Hoekstra, O. S.
    Stokkel, M. P. M.
    van Brummelen, E.
    Mulder, E.
    van Dongen, G. A. M. S.
    Vugts, D. J.
    Verheul, H.
    Nayak, T. K.
    Saro, J.
    Evers, S.
    Schellens, J. H. M.
    van Oordt, C. W. Menke-van der Houven
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S178 - S179
  • [25] PET-CT/FACS platform to detect the biodistribution of radioisotope 89Zr PD-1 inhibitor in syngeneic tumor models
    Tang, Xuzhen
    Wang, Fuyang
    Chen, Junyi
    Zeng, Xuanming
    Liu, Zhibo
    Ji, Qunsheng
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP)
    Nakaigawa, Noboru
    Hasumi, Hisashi
    Utsunomiya, Daisuke
    Yoshida, Keisuke
    Ishiwata, Yoshinobu
    Oka, Takashi
    Hayward, Colin
    Makiyama, Kazuhide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (08) : 873 - 879
  • [27] Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
    Altena, R.
    Tzortzakakis, A.
    Blomgren, A.
    Jussing, E.
    Ekman, S.
    Tran, T.
    Axelsson, R.
    Bergh, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S402 - S403
  • [28] Current advances in ligand design for inorganic positron emission tomography tracers 68Ga, 64Cu, 89Zr and 44Sc
    Price, Thomas W.
    Greenman, John
    Stasiuk, Graeme J.
    DALTON TRANSACTIONS, 2016, 45 (40) : 15702 - 15724
  • [29] A PILOT STUDY OF ZR89-J591 POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
    Green, David
    Fareedy, Shoaib B.
    Osborne, Joseph R.
    Robinson, Brian D.
    Goldenberg, Sagit
    Tewari, Ashutosh
    Herman, Michael
    Bander, Neil
    Scherr, Douglas S.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E278 - E279
  • [30] New bifunctional ligands of Zr-89 for potential applications in antibody-targeted positron emission tomography (PET) imaging and precision medicine
    Chen, Yanda
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
12345